Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: HUM stock price vs TSLA: inconclusive — current versus $4.10K implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at TSLA's multiple
Implied fair value · at HUM's multiple
Needs HUM P/E.
Close Dec 31, 2025
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
HUMANA INC · implied price per share
Bear
$238.74
Base
$269.81
Bull
$310.28
Tesla, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
UNITEDHEALTH GROUP INC
HUM vs UNH
Elevance Health, Inc.
HUM vs ELV
CVS HEALTH Corp
HUM vs CVS
Cigna Group
HUM vs CI
CENTENE CORP
HUM vs CNC
Oscar Health, Inc.
HUM vs OSCR
Lucid Group, Inc.
HUM vs LCID
FORD MOTOR CO
HUM vs F
General Motors Co
HUM vs GM
Enphase Energy, Inc.
HUM vs ENPH
PLUG POWER INC
HUM vs PLUG
COPART INC
HUM vs CPRT
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Edwyn research
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe HUM’s strong revenue growth and high ROIC can eventually expand margins toward TSLA levels, then HOLD or add selectively because the current price is still within the historical band and the balance sheet quality is not distressed; otherwise, the stock looks difficult to justify against TSLA on the provided TSLA-based P/E output.
The valuation gap is extreme: HUM’s current price of $361.83 sits far below the P/E-implied price of $4,097.45, implying 1032.4% upside on the model but also signaling that the comparison framework is likely distorted. HUM also trades above its historical band midpoint, with current price near the upper end of the $325.65-$398.01 range.
Supporting Metrics
